NUCYNTA® ER (Tapentadol Extended-Release Tablets) Receives FDA Approval for … – MarketWatch (press release)

posted on Aug 26 by in the Uncategorized category

NUCYNTA® ER (Tapentadol Extended-Release Tablets) Receives FDA Approval for ...
MarketWatch (press release)
NUCYNTA® ER may be expected to have additive effects when used in conjunction with alcohol, other opioids, or illicit drugs that cause CNS depression, because respiratory depression, hypotension, hypertension, and profound sedation, coma, ...

and more »

Leave a Response

Get Adobe Flash playerPlugin by wpburn.com wordpress themes